Kalpataru Multiplier Ltd.

Our Bank & DP Click for Online Payment MF portfolio login smart way to invest in gold
Sovereign gold bond(SGB) Exchange trades funds(ETF)
CLOSE

Download our app Kalpataru Share trading from Google/App Store and transfer fund instantly.

Company Profile
more from company profile
HomeMarkets Company Profile Smart Quotes

Smart Quotes

JENBURKT PHARMACEUTICALS LTD.

NSE : NABSE : 524731ISIN CODE : INE354A01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE1177.0011.05 (+0.95 %)
PREV CLOSE () 1165.95
OPEN PRICE () 1174.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2822
TODAY'S LOW / HIGH ()1152.15 1194.00
52 WK LOW / HIGH () 9441410
NSE
This Company is not listed in NSE
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 1985

Management Info :

Ashish U Bhuta - Chairman Ashish U Bhuta - Managing Director

Registered Office :

Address : Nirmala Apartments,93 Jayprakash Road,Andheri (West),
Mumbai,
Maharashtra-400058

Phone : 022-67603603

Website : www.jenburkt.com

Registrar's Details : Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE
NEWS
05May Appointment of Director
Inter alia, approved:- 1. A dividend of 220.70/- (207%) per equity shar..
28Apr Dividend Announcement
Final Dividend & Audited Results & A.G.M. & Quarterly Results
14Apr Jenburkt Pharmaceuticals informs about
Pursuant to SEBI Circular SEBI/HO/DDHS/CIR/2021/613 dated 10th August, 2..
28Oct Jenburkt Pharmaceuticals informs about
Jenburkt Pharmaceuticals has informed that it enclosed Standalone Unaudi..
23Jun Jenburkt Pharmaceuticals informs about
With reference to letter no. JPL/CS/2206/2024 dated 20th June, 2025, Jen..
Financials
in Millions
QTR Mar 26 ANNUAL 26
Net Profit108.5347.36
Gross Profit 137.09 465.19
Operating Profit 185.98540.4
Net Sales 446.321687.41
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 27125.05 (0.84%)
M.Cap ( in Cr)
57933.88
Divi's Lab (BSE)
 6789.10 (2.19%)
M.Cap ( in Cr)
180253.17
Procter&Gamble Healt (BSE)
 5220.50 (2.30%)
M.Cap ( in Cr)
8664.88
CORONA Remedies (BSE)
 1706.30 (4.86%)
M.Cap ( in Cr)
10511.58
Acutaas Chemicals (BSE)
 2820.00 (2.81%)
M.Cap ( in Cr)
23141.69
Shareholding Pattern
NON-INSTITUTION 53.25%
PROMOTERS 46.64%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
Mf Holding
Scheme NameHold(%)
No Data Found
ATTENTION INVESTORS

Kalpataru Multiplier Ltd.

Kalpataru is a wishful Divine Tree and in present context a widely Trusted, Time tested and Transparent Share Broker, Mutual Fund Distributor and D.P. of this region.

Mobile Trading App
Mobile Trading IOS App
Call Us 0755-4350141/142/143, 9425008895
Mutual Funds 0755-4276725, 4276726
Email Uskmlho@kalpatarumulti.com

registration nos:

Kalpataru Multiplier Ltd.: SEBI Regn. No. INZ000259437

Registered address: Kalpataru House, 18 Itwara, Bhopal (MP) – 462001

Member Member ID
Bombay Stock Exchange Ltd.(BSE) 3016
National Stock Exchange Ltd. 11152
Multi Commodity Exchange(MCX) 16020

Depository Participant of CDSL DP-ID 12031600

(SEBI Regn No. IN-DP-CDSL-221-2003)

In absence of response/ complaint not addressed to your satisfaction, you may lodge a complaint and reach out to us on:

SMART ODR PORTAL @ https://smartodr.in/login

Copyright © 2016 Kalpataru Multiplier Ltd.
Designed ,Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
SENSEX74608.9849.74 (0.07%)
NIFTY23428.7049.15 (0.21%)
Dow Jones 49760.5656.09 (0.11%)
Nasdaq 26088.20-185.93 (-0.71%)
CLOSE Disclosure
CLOSE

INFORMATION UNDER THE HEAD SHOULD BE ADDED AS FOLLOWS

  • Sharing of trading credentials - login id & password including OTP's.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing / selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through Whatsapp, Telegram, YouTube, Facebook, SMS, Calls, etc.
  • Trading in "Options" based on recommendations from unauthorised / unregistered investment advisors and influencers.
CLOSE SEBI